Skip to content
Screener

LivaNova LIVN Neuromodulation — Net revenue

Other segment segments

Cardiopulmonary
$221.58M+11.2%

Similar metrics at other companies

Installed Building Products logo
IBPNet revenue, Installation — Net revenue
$710.7M-0.7%
Marqeta logo
MQPlatform services revenue, net — Net revenue
$156.23M+18.5%
Visa logo
VOther revenue — Net revenue
$1.5B+45.5%
Visa logo
VService revenue — Net revenue
$4.92B+13.7%
Cavco Industries logo
CVCODelivery, setup and other revenues — Net revenue
$23.21M-15.9%
Advanced Micro Devices logo
AMDDatacenter — Net revenue
$10.25B+37.8%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
United States126,556117,226241,956225,560
Europe (1)19,85817,73038,20632,924
Rest of World (1)20,53116,71438,57132,079
166,945151,670318,733290,563
Other Revenue (2)2,0661,5823,8813,224
Total Company
United States199,350188,474384,028357,638
Europe (1)81,81766,776157,469126,477

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's neuromodulation — net revenue?
LivaNova (LIVN) reported neuromodulation — net revenue of $166.95M in Q2 2026.
How has LivaNova's neuromodulation — net revenue changed year-over-year?
LivaNova's neuromodulation — net revenue increased by 10.1% year-over-year, from $151.67M to $166.95M.
What is the long-term trend for LivaNova's neuromodulation — net revenue?
Over 4 years (2021 to 2025), LivaNova's neuromodulation — net revenue has grown at a 6.8% compound annual growth rate (CAGR), from $456.17M to $592.81M.
What does neuromodulation — net revenue mean?
Represents the total gross sales generated by the Neuromodulation business segment after deducting returns, allowances, and discounts. This metric serves as a primary indicator of market demand and the segment's ability to scale its medical device product offerings.

Ask your AI about LivaNova's neuromodulation — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude